David Allen, DO
Internal Medicine · Omaha, NENPI 1295884021
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 467 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 467 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$1K
- Novo Nordisk$510
- AstraZeneca$481
- Lilly USA, LLC$391
- Novartis$265
- plus $3K from 54 others
What the payments were for
- Food & beverage$7,531100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,537 in reported general payments places this provider in the 95th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $154,465 |
| JardianceEmpagliflozin | 119 | $113,691 |
| EliquisApixaban | 147 | $113,406 |
| ProvigilModafinil | 12 | $50,495 |
| MounjaroTirzepatide | 27 | $42,479 |
| TrulicityDulaglutide | 26 | $40,664 |
| FarxigaDapagliflozin Propanediol | 28 | $35,770 |
| XareltoRivaroxaban | 21 | $25,854 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $20,300 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $18,249 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $14,349 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $13,654 |
| MyrbetriqMirabegron | 22 | $12,153 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $11,600 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 28 | $8,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $510 | $154,465124 claims |
| Boehringer IngelheimJardiance | $93 | $113,691119 claims |
| PfizerEliquis | $201 | $113,406147 claims |
| Lilly USA, LLCMounjaro, Trulicity | $391 | $83,14353 claims |
| AstraZenecaFarxiga | $481 | $35,77028 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix, Arnuity Ellipta | $62 | $35,157104 claims |
| Johnson & JohnsonXarelto | $106 | $25,85421 claims |
| Astellas Pharma US IncMyrbetriq | $74 | $12,15322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Omaha
- Brian BoerOmaha$142K
- Adam BurdorfOmaha$29K
- David SharpOmaha$26K
- David ShinOmaha$26K
- Nikhil JaganOmaha$20K
- Clayton SchroederOmaha$14K
- Ali NayfehOmaha$12K
- Kirtibala GuptaOmaha$12K
- Chad VokounOmaha$11K
- Joel MichalskiOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.